首页>投融资
Amphivena Therapeutics
C轮
Amphivena Therapeutics Inc (a subsidiary of Affimed) is a preclinical stage company based in California foucused on developing an innovative immunotherapy for hematologic malignancies,.In April 2015, Amphivena entered into an agreement with Janssen Biotech, that would grant Janssen the exclusive right at its discretion to acquire Amphivena following IND approval of immunotherapy for hematologic malignancies.In July 2013, Amphivena raised $14 M in a Series A financing led by MPM Capital.By November 2017, the company had raised $19.5 million from series A financing led by MPM Capital
基本信息
-
公司全称Amphivena Therapeutics Inc
-
类型免疫肿瘤学公司
-
产业领域医疗服务、生物药
-
公司人数15~50人
-
地址45 Juniper St Apt 3 SAN FRANCISCO CALIFORNIA 94103-3759; US; Telephone: +14159946455;
-
联系电话14159946455
-
邮箱info@amphivena.com
-
成立时间
投融资
-
2019-09-25C轮6200万美元Aju IB InvestmentTekla Capital ManagementIndustrial InvestorsClough Capital PartnersMPM Capital启明创投NanoDimensionNewton Investment ManagementKorys
相关投融资企业
IPO后其他轮次
Cerus Corporation于1991年在美国加州成立，并于1996年在特拉华州重新合并成立，该公司是一家生物医药产品公司，专注于“拦截血液系统”的商业化推广，以加强血液安全。设计该“拦截系统”是为了灭活原本用于输血的捐献血液成分中的血源性病原体。目前，该公司在欧洲，俄罗斯，中东和世界其他地区中的选定国家中销售血小板和血浆的“拦截系统”。该公司还在美国和其他国家寻求监管机构批准其血小板和血浆系统。“拦截”红细胞系统目前正处于临床开发中。
C轮
Amphivena Therapeutics Inc (a subsidiary of Affimed) is a preclinical stage company based in California foucused on developing an innovative immunotherapy for hematologic malignancies,.In April 2015, Amphivena entered into an agreement with Janssen Biotech, that would grant Janssen the exclusive right at its discretion to acquire Amphivena following IND approval of immunotherapy for hematologic malignancies.In July 2013, Amphivena raised $14 M in a Series A financing led by MPM Capital.By November 2017, the company had raised $19.5 million from series A financing led by MPM Capital
债权融资
Cerus Corporation于1991年在美国加州成立，并于1996年在特拉华州重新合并成立，该公司是一家生物医药产品公司，专注于“拦截血液系统”的商业化推广，以加强血液安全。设计该“拦截系统”是为了灭活原本用于输血的捐献血液成分中的血源性病原体。目前，该公司在欧洲，俄罗斯，中东和世界其他地区中的选定国家中销售血小板和血浆的“拦截系统”。该公司还在美国和其他国家寻求监管机构批准其血小板和血浆系统。“拦截”红细胞系统目前正处于临床开发中。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息